Autoantibodies in Alzheimer's disease: potential biomarkers, pathogenic roles, and therapeutic implications
doi: 10.7555/JBR.30.20150131
This work was supported in part by grants from the National Institute of Health (HL117652) (to JW) and the Academic Health Center (Faculty Research Development Program) of the University of Minnesota(to LL and JW).
- Received Date: 2015-09-15
- Publish Date: 2016-09-28
-
Key words:
- Alzheimer's disease /
- autoimmune /
- autoantibody /
- biomarker /
- pathogenesis /
- immunotherapy
Abstract: Alzheimer's disease (AD) is a prevalent and debilitating neurodegenerative disorder in the elderly. The etiology of AD has not been fully defined and currently there is no cure for this devastating disease. Compelling evidence sug-gests that the immune system plays a critical role in the pathophysiology of AD. Autoantibodies against a variety- of molecules have been associated with AD. The roles of these autoantibodies in AD, however, are not well -understood.This review attempts to summarize recent findings on these autoantibodies and explore their potential as diagnostic/ prognostic biomarkers for AD, their roles in the pathogenesis of AD, and their implications in the development of effective immunotherapies for AD.
Citation: | Jianming Wu, Ling Li. Autoantibodies in Alzheimer's disease: potential biomarkers, pathogenic roles, and therapeutic implications[J]. The Journal of Biomedical Research, 2016, 30(5): 361-372. doi: 10.7555/JBR.30.20150131 |